Wockhardt LimitedNSE: WOCKPHARMA

Press Release Oct 16 2024

· Issued by Wockhardt Limited

Filed with NSE · · 3 pages · English

Summary by 6ix AI

Wockhardt Limited has submitted a press release regarding the filing of its fast-acting insulin Aspart injection with the Drugs Controller General of India. This filing highlights Wockhardt's commitment to diabetes management amid the rising prevalence of diabetes in India and globally. The product aims to enhance quality and accessibility for patients, with plans for various delivery formats. Wockhardt is also developing additional diabetes care solutions to strengthen its portfolio.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Release

Wockhardt Limited has informed the Exchange regarding a press release dated October 16, 2024, titled - Wockhardt files fast-acting Insulin Aspart injection (ASPARAPIDTM) with DCGI; strengthens commitment to diabetes management .

Wockhardt Limited on 6ix

Earlier from Wockhardt

Later from Wockhardt

All Wockhardt news releases